Latest Hansa Biopharma News & Updates

See the latest news and media coverage for Hansa Biopharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Hansa Biopharma

Developer of immunomodulatory treatments for rare immunological diseases

hansabiopharma.com
Headquarters
Lund, Sweden
Founded year
2007
Company type
Public company
Number of employees
125–200

Last updated

Latest news about Hansa Biopharma

In short: Hansa Biopharma secured funding to mid-2027 and received an FDA PDUFA date of December 19, 2026, for its imlifidase kidney transplant application.

Company announcements

  • Hansa Biopharma

    Hansa Biopharma issues notice for AGM

    The meeting occurs June 1, 2026, in Lund, covering financial reports, board elections, remuneration, and incentive programs.

  • Hansa Biopharma

    Hansa Biopharma reports Q1 2026 financial results

    Revenue falls to 34.6 MSEK from 66.3 MSEK. FDA sets PDUFA date for imlifidase BLA on December 19, 2026. Secures USD 30 million convertible note, extending runway.

  • Hansa Biopharma

    Hansa Biopharma publishes 2025 Annual and Sustainability Reports

    The reports highlight Phase 3 success, BLA submission, revenue growth, financial strengthening, pipeline advances, and leadership changes. Published March 26, 2026.

  • Hansa Biopharma

    Hansa Biopharma announces USD 30 million convertible note financing

    The financing with Athyrium extends cash runway into mid-2027 and supports imlifidase US launch. Notes mature in 2031 with 3% interest.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Hansa Biopharma

Track Hansa Biopharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Hansa Biopharma competitors & trending companies

Browse news for competitors to Hansa Biopharma and other trending companies.